Ontoy, Elmo .

HRN: 26-51-71  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/13/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
01/13/2025
01/20/2025
IV
600mg
Q6
Infected Wound
Waiting Final Action 
01/14/2025
CEFTRIAXONE 1G (VIAL)
01/14/2025
01/21/2025
IV
2g
Od
Infected Wound
Waiting Final Action 
01/14/2025
MUPIROCIN 2%, 15G (TUBE)
01/14/2025
01/21/2025
TOPICAL
2%
BID
Infected Wound
Waiting Final Action 
01/15/2025
MUPIROCIN 2%, 15G (TUBE)
01/15/2025
01/28/2025
TOPICAL
Apply Thin Coat
BID
Infected Wound
Waiting Final Action 
01/19/2025
CLARITHROMYCIN 500MG (CAP)
01/19/2025
01/26/2025
PO
500mg
BID
Pneumonia
Waiting Final Action 
01/22/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/22/2025
02/04/2025
IV
2.25gm
Q8
Septicemia
Waiting Final Action 
01/23/2025
MUPIROCIN 2%, 15G (TUBE)
01/23/2025
02/13/2025
TOPICAL
Apply To Affected Area
BID
Infected Wound
Waiting Final Action 
01/24/2025
CLARITHROMYCIN 500MG (CAP)
01/24/2025
01/24/2025
PO
500mg
BID
Cap
Waiting Final Action 
01/24/2025
CLARITHROMYCIN 500MG (CAP)
01/19/2025
01/25/2025
PO
250mg
BID
Cap
Waiting Final Action 
01/31/2025
MUPIROCIN 2%, 15G (TUBE)
01/31/2025
02/06/2025
TOPICAL
Apply BID
BID
Soft Tissue Infection
Waiting Final Action 
02/08/2025
CEFIXIME 200MG (CAP)
02/08/2025
02/15/2025
PO
200 Mg
BID
Infected Wound Scapular Area
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: